Cargando…

Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs

BACKGROUND: Genetic therapies are a promising treatment for children born with spinal muscular atrophy (SMA); however, their high price tags can evoke coverage restrictions. OBJECTIVE: To assess variation in coverage guidelines across fee-for-service state Medicaid programs for 2 novel genetic thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballreich, Jeromie, Ezebilo, Ijeamaka, Khalifa, Banda Abdallah, Choe, Joshua, Anderson, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372955/ https://www.ncbi.nlm.nih.gov/pubmed/34949120 http://dx.doi.org/10.18553/jmcp.2022.28.1.39

Ejemplares similares

Medicaid Fees and the Medicare Fee Schedule: An Update
por: Norton, Stephen A.
Publicado: (1995)

Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021
por: Clemans-Cope, Lisa, et al.
Publicado: (2022)

Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry
por: Padula, William V., et al.
Publicado: (2018)

The Impact of Medicaid Adoption of the Medicare Fee Schedule
por: Holahan, John, et al.
Publicado: (1993)

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
por: Lin, Dora H., et al.
Publicado: (2018)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Children's Mental Health Services in Fee-for-Service Medicaid
por: Larson, Mary Jo, et al.
Publicado: (2004)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Branded prescription drug spending: a framework to evaluate policy options
por: Ballreich, Jeromie, et al.
Publicado: (2017)

Proteomic assessment of a cell model of spinal muscular atrophy
por: Wu, Chia-Yen, et al.
Publicado: (2011)

Estimating & comparing greenhouse gas emissions for existing intramuscular COVID-19 vaccines and a novel thermostable oral vaccine
por: Patenaude, Bryan, et al.
Publicado: (2022)

Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19
por: Patenaude, Bryan, et al.
Publicado: (2022)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019
por: Ballreich, Jeromie M., et al.
Publicado: (2021)

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023)

State Medicaid Programs Bring Managed Care Tenets to Fee for Service
por: Keast, Shellie L., et al.
Publicado: (2016)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019
por: Plummer, Elizabeth, et al.
Publicado: (2022)

Mitochondrial abnormalities in spinal and bulbar muscular atrophy
por: Ranganathan, Srikanth, et al.
Publicado: (2009)

Rapid molecular diagnosis of spinal muscular atrophy
por: Mittal, Balraj
Publicado: (2012)

Cardiac involvement in patients with Spinal Muscular Atrophies
por: Palladino, Alberto, et al.
Publicado: (2011)

Clinical features of spinal and bulbar muscular atrophy
por: Rhodes, Lindsay E., et al.
Publicado: (2009)

Disease burden of spinal muscular atrophy in Germany
por: Klug, Constanze, et al.
Publicado: (2016)

Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy
por: Ahmad, Saif, et al.
Publicado: (2016)

Longitudinal characterization of biomarkers for spinal muscular atrophy
por: Bonati, Ulrike, et al.
Publicado: (2017)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Swallowing markers in spinal and bulbar muscular atrophy
por: Banno, Haruhiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_okii021mg91290t3972tc30vil